Category: MassDevice.com Earnings RoundupSyndicate content

Spectranetics to boost Stellarex spend

April 24, 2015 by Brad Perriello

Spectranetics says it plans to boost its R&D spend on the Stellarex drug-eluting balloon it bought from Covidien.

Spectranetics to boost Stellarex spend

Bard shares tick up on Q1 earnings beat

April 24, 2015 by Brad Perriello

Share prices tick up for C.R. Bard after it reports a 1st-quarter earnings beat.

Bard shares tick up on Q1 earnings beat

C.R. Bard (NYSE:BCR) shares gained today after the medical products giant reported 1st-quarter earnings that topped expectations on Wall Street, despite a poor quarterly comparison for its Lutonix drug-eluting balloon.

TAVI: Edwards CEO says Sapien 3 could hit U.S. market this year

April 24, 2015 by Brad Perriello

Edwards Lifesciences CEO Michael Mussallem says the company now expects the FDA to approve its next-generation Sapien 3 replacement heart valve this year.

TAVI: Edwards CEO says Sapien 3 could hit U.S. market this year

Baxter logs Q1 sales, earnings beats

April 23, 2015 by Brad Perriello

Baxter International reports 1st-quarter results that top its own and Wall Street's sales & earnings expectations.

Baxter logs Q1 sales, earnings beats

Investors bid shares of Baxter (NYSE:BAX) up this morning after the healthcare giant reported sales and earnings that beat expectations on Wall Street and its own prior guidance, despite declines for both numbers.

Abbott logs Q1 profits beat as branded generics sales jump

April 22, 2015 by MassDevice

Abbott's 1st-quarter profits top expectations as sales of its branded generic drugs jump.

Abbott logs Q1 profits beat as branded generics sales jump

St. Jude Medical's Q1 beats own guidance and Wall Street's

April 22, 2015 by Brad Perriello

St. Jude Medical's 1st-quarter earnings top both its own guidance and Wall Street's outlook, prompting the medical device company to boost its 2015 sales forecast.

St. Jude Medical's Q1 beats own guidance and Wall Street's

Strong comp buoys Stryker's Q1 bottom line

April 22, 2015 by Brad Perriello

Stryker's 1st-quarter profits surge 220% on a strong comparison with Q1 2014, when recall expenses took $344 million from the bottom line.

Strong comp buoys Stryker's Q1 bottom line

Stryker (NYSE:SYK) yesterday topped Wall Street's earning forecast with its 1st-quarter results, buoyed by a strong comparison with Q1 2014.